Navigation Links
Delcath to Present at the Lazard Healthcare Conference on November 15
Date:11/11/2011

esults to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
2. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
3. FDA Schedules Delcath Pre-New Drug Application Meeting Date
4. Delcath Announces Completion of Regulatory Notification Process in New Zealand
5. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
6. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
7. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
8. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
9. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
10. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
11. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Digirad Corporation (Nasdaq: DRAD) today announced that it has sent ... ), a healthcare commercialization services company, responding to PDI,s ... Digirad calls upon PDI to immediately ... operate in the ordinary course of business and to ... on acquisitions or other extraordinary transactions. Digirad believes that ...
(Date:10/31/2014)... DIEGO, Oct. 31, 2014 Mast Therapeutics, Inc. ... financial results for the quarter ended September 30, 2014. ... Executive Officer, said:  "The third quarter was productive for ... study of MST-188 for sickle cell disease is on ... year. We now have opened 50 study sites in the ...
(Date:10/31/2014)... 2014 Today, Analysts Review released ... CELG ), Bristol-Myers Squibb Co. (NYSE: BMY ... Sanofi SA (NYSE: SNY ) and Actavis ... ahead of publication. To reserve complementary membership, limited openings ... Corporation Research Reports ,On October 23, 2014, Celgene Corporation ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... 2011 A coalition of advocacy groups and patients yesterday ... District of Columbia Circuit to compel the Obama Administration to ... under the provisions of the Controlled Substances Act (CSA). ... states with medical marijuana laws to expedite efforts to change ...
... 24, 2011 American Scientific Resources, Incorporated (OTCQB: ... with the S.E.C. containing results for the quarter ... http://www.sec.gov/Archives/edgar/data/1114605/000114420411031846/0001144204-11-031846-index.htm to review the entire 10-Q filing. ... The Company would also like to direct investors ...
Cached Medicine Technology:Federal Court Asked to Compel Decision in Marijuana Scheduling Action 2Federal Court Asked to Compel Decision in Marijuana Scheduling Action 3American Scientific Resources, Inc. Announces Quarterly Results 2
(Date:11/1/2014)... Tara Haelle HealthDay Reporter ... can both sense adult anger and alter their behavior in ... sponges," said study co-author Andrew Meltzoff, co-director of the University ... "They learn not only from their own direct social experiences ... He said he was most surprised at how emotionally ...
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... of duration of treatment and cost, patients with ... partial breast irradiation (APBI) with proton therapy versus ... from The University of Texas MD Anderson Proton ... analysis study based on typical patient characteristics, researchers ... for eight different types of partial and whole ...
Breaking Medicine News(10 mins):Health News:Study Shows How Toddlers Adjust to Adult Anger 2Health News:Study Shows How Toddlers Adjust to Adult Anger 3Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... , TUESDAY, Nov. 2 (HealthDay News) -- The U.S. Food ... properly monitoring the safety of medical devices, the authors of ... to approve both drugs and medical devices, but the investigators ... is lax in both its initial approval of devices and ...
... Ariz. Volunteering is known to provide health benefits ... study finds that older adults with functional limitations (trouble ... to reap the benefits from helping others. ... impact of volunteering on risk of mortality was stronger ...
... vaccination and health programs may help states improve their ... a new study suggests. The study -- conducted ... collaboration with the Centers for Disease Control and Prevention ... the striking state-by-state variation in U.S. H1N1 flu vaccination ...
... published in November 3 edition of Journal of ... MPH, MBA, professor of Health Policy and Management at ... for key improvements to primary care in order to ... adults with multiple chronic conditions. Boult and his co-author, ...
... Reporter , TUESDAY, Nov. 2 (HealthDay News) -- Only one in ... asthma symptoms in kids, a new study found. What,s ... symptom, according to the study, which was to be presented Nov. ... Physicians, in Vancouver, Canada. "We found that about 35 ...
... includes three articles with leading research, highlighted below. ... in Patients With Acute Coronary Syndrome ROCHESTER, ... present with acute coronary syndrome had significantly higher rates of ... risk profiles. "The leaves of khat, a leafy ...
Cached Medicine News:Health News: FDA Failing to Monitor Safety of Medical Devices: Report 2Health News: FDA Failing to Monitor Safety of Medical Devices: Report 3Health News: FDA Failing to Monitor Safety of Medical Devices: Report 4Health News:Study shows volunteering benefits those with functional limitations 2Health News:Study shows volunteering benefits those with functional limitations 3Health News:Strengthening routine flu vaccination and health programs may improve pandemic vaccinations 2Health News:Strengthening routine flu vaccination and health programs may improve pandemic vaccinations 3Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 2Health News:Geriatrician advocates for improvements to primary care to meet the needs of older adults 3Health News:Many Coaches Unprepared for Student-Athletes' Asthma 2Health News:Many Coaches Unprepared for Student-Athletes' Asthma 3Health News:Mayo Clinic Proceedings: November highlights 2
... LP is a super-light polypropylene mesh which ... reaction is reduced considerably. Optilene Mesh LP ... open hernia repair procedures. It perfectly conforms,to ... Optilene Mesh LP adapts to the movements ...
... Premilene Mesh Self-Forming Plug is a mesh ... as well as primary inguinal hernias and ... the defect and fills it completely. Premilene ... made of the established Premilene Mesh. The ...
... The advanced optical system of the Applied ... of illumination. There are six models to ... spot options. Spot size ranges from 15 ... headlight system is compatible with any of ...
... The use of some micro vascular ... and thrombosis. With use, Stainless steel changes ... is known that pressures above 30g/mm2 may ... are made from titanium which does not ...
Medicine Products: